United Therapeutics hits speed bump in its quest for new drug approval

Four months after seeking federal approval to start selling its latest product, United Therapeutics Corp. (NASDAQ: UTHR) has its response — and it's not exactly all the Silver Spring drugmaker had hoped. The company said Monday that the Food and Drug Administration has declined to give its stamp of approval for Tyvaso DPI, an inhaler that dispenses a dry powder form of the pulmonary arterial hypertension (PAH) drug, treprostinil. T he company had sought the agency’s green light in April to take…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news